Sheri Holmen on Understanding Drivers of Melanoma Metastasis

Sheri Holmen, PhD
Published: Thursday, Nov 19, 2015



Sheri Holmen, PhD, investigator, Associate Professor in the Department of Surgery, Adjunct Professor in the Department of Oncological Sciences, Huntsman Cancer Institute, the University of Utah School of Medicine, discusses understanding drivers for melanoma metastasis.

The biggest unmet clinical need in melanoma is treating metastatic disease, says Holmen. Although there have been many new FDA approved therapies for melamine over the past five years, many patients still succumb to metastatic disease, often in the brain.

Holmen’s lab created an in-vivo model that allows oncologists to better understand the biology behind melanoma brain metastasis and test new therapies more rapidly. It is an immune combatant model, which means that both new immunotherapies and and targeted therapies can be tested in it, says Holmen. By using this model Holmen’s team has found evidence that AKT pathway may drive metastasis.

<<< View more from the 2015 SMR Congress



Sheri Holmen, PhD, investigator, Associate Professor in the Department of Surgery, Adjunct Professor in the Department of Oncological Sciences, Huntsman Cancer Institute, the University of Utah School of Medicine, discusses understanding drivers for melanoma metastasis.

The biggest unmet clinical need in melanoma is treating metastatic disease, says Holmen. Although there have been many new FDA approved therapies for melamine over the past five years, many patients still succumb to metastatic disease, often in the brain.

Holmen’s lab created an in-vivo model that allows oncologists to better understand the biology behind melanoma brain metastasis and test new therapies more rapidly. It is an immune combatant model, which means that both new immunotherapies and and targeted therapies can be tested in it, says Holmen. By using this model Holmen’s team has found evidence that AKT pathway may drive metastasis.

<<< View more from the 2015 SMR Congress




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Oncology Briefings™: Harnessing the Predictive Powers of Biomarkers in Immuno-OncologyJul 31, 20191.0
Publication Bottom Border
Border Publication
x